How to Cite
Abstract
Sin resumen
References
- Morton DL, Eilber FR, Joseph WL et al. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg. 1970;172:740–9.
- Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92.
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
- Chapman PB, Hauschild A, Robert C, Haanen PA, Larkin J, Dummer R et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 30; 364 (26): 2507–16.
- Robert C, Thomas L BI et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;30;364(26):2517–26.
- Wolchock JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, et al. CheckMate 067 6.5 year outcomes in patients with advanced melanoma ASCO 2021 Journal of Clinical Oncology 2021 39:15_suppl, 9506-9506
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Archives of Pathology